8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  April 30, 2007

BRUKER BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation) 000-30833
(Commission
File Number) 04-3110160
(IRS Employer
Identification No.)

40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:(978) 663-3660

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act

o   Soliciting material pursuant to Rule 14a-12 of the Exchange Act

o   Pre-commencement communications pursuant to Rule 14d-2(b) Exchange Act

o   Pre-commencement communications pursuant to Rule 13e-4(c) Exchange Act

Section 2 — Financial Information

Item 2.02.  Results of Operations and Financial Condition

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On April 30, 2007, Bruker BioSciences Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2007.  A copy of the press release is attached hereto as Exhibit 99.1.

2

Section 9 — Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits

Number
99.1	Press release dated April 30, 2007.

3

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRUKER BIOSCIENCES CORPORATION (Registrant)
Date: April 30, 2007	By:	/s/ Frank H. Laukien
		Frank H. Laukien, Ph.D. Chief Executive Officer and President

4

Exhibit Index

Exhibit Number	Exhibit Name	Location
99.1	Press release dated April 30, 2007.	Furnished herewith*

*Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

5

EX-99.1

Exhibit 99.1

Bruker BioSciences Reports First Quarter 2007 Year-over-Year Pooled Revenue Growth of 16% and Strong Operating Income Growth

BILLERICA, Mass., May 1, 2007 (BUSINESS WIRE)  —  Bruker BioSciences Corporation (NASDAQ: BRKR) today reported financial results for the three months ended March 31, 2007.

On July 1, 2006, Bruker BioSciences completed its acquisition of Bruker Optics Inc., which was accounted for as a pooling of interests.  As a result of this required GAAP accounting treatment, all historical financials have been pooled as if the companies had always been combined.

For the first quarter of 2007, revenue increased by 16.5% to $110.5 million, compared to pooled revenue of $94.9 million in the first quarter of 2006.  Excluding the effects of foreign currency translation, first quarter 2007 revenue increased by 10.6% year-over-year.

Net income in the first quarter of 2007 was $3.9 million, or $0.04 per diluted share, compared to pooled net income of $3.3 million, or $0.03 per diluted share, in the first quarter of 2006.

Operating income in the first quarter of 2007 was $7.8 million, up 59.5% compared to operating income of $4.9 million in the first quarter of 2006.  Excluding acquisition related charges of $1.2 million in Q1 2006, operating income increased 28.4% year-over-year.

Commenting on the first quarter, Frank Laukien, President and CEO, said: “I am very pleased that we started 2007 with strong year-over-year growth and solid improvements in our gross margins and operating income.  We believe the combination of our competitive product offerings, healthy backlog and strong end-markets position us well for continued success throughout 2007.”

EARNINGS CONFERENCE CALL

Bruker BioSciences will host an operator-assisted earnings conference call at 8 a.m. Eastern Time on Tuesday, May 1, 2007.  To listen to the webcast, investors can go to www.bruker-biosciences.com and click on the live web broadcast symbol.  The webcast will be available through the Company web site for 30 days.  Investors can also listen and participate on the telephone in the US and Canada by calling 888-339-2688, or 617-847-3007 outside the US and Canada.  Investors should refer to the Bruker BioSciences Quarterly Earnings Call.  A telephone replay of the conference call will be available one hour after the conference call by dialing 888-286-8010 in the US and Canada, or 617-801-6888 outside the US and Canada, and then entering replay pass code 16589667.

ABOUT BRUKER BIOSCIENCES

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc.  Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis and spark-OES tools.  Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of chemical, biological, radiological and nuclear (CBRN) detection products for homeland security.  Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology.  For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our reorganization strategies, risks related to the integration of businesses we have acquired or may acquire in the future,  technological approaches, product development, market acceptance, cost and pricing of our products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Condensed consolidated statements of operations and balance sheets follow for Bruker BioSciences Corporation.

2

Bruker BioSciences Corporation
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)

	Three Months Ended March 31,
	2007			2006
Product revenue	$	95,362		$	83,841
Service revenue	14,991			10,371
Other revenue	154			644
Total revenue	110,507			94,856
Cost of product revenue	47,811			44,713
Cost of service revenue	10,068			6,387
Total cost of revenue	57,879			51,100
Gross profit margin	52,628			43,756
Operating Expenses:
Sales and marketing	23,764			18,832
General and administrative	7,492			6,607
Research and development	13,613			12,275
Acquisition related charges	—			1,176
Total operating expenses	44,869			38,890
Operating income	7,759			4,866
Interest and other income (expense), net	(525		)	1,681
Income before income tax provision and minority interest in consolidated subsidiaries	7,234			6,547
Income tax provision	3,267			3,240
Income before minority interest in consolidated subsidiaries	3,967			3,307
Minority interest in consolidated subsidiaries	86			48
Net income	$	3,881		$	3,259
Net income per share:
Basic	$	0.04		$	0.03
Diluted	$	0.04		$	0.03
Weighted average shares outstanding:
Basic	102,820			101,186
Diluted	105,361			101,480

3

Bruker BioSciences Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

	March 31,		December 31,
	2007		2006
	(unaudited)
ASSETS
Current assets:
Cash and short-term investments	$	55,692	$	52,147
Accounts receivable, net	75,110		79,604
Due from affiliated companies	7,536		9,028
Inventories	157,616		134,504
Other current assets	23,121		19,461
Total current assets	319,075		294,744
Property and equipment, net	91,410		90,349
Intangible and other assets	52,609		48,094
Total assets	$	463,094	$	433,187
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Short-term borrowings	$	11,601	$	21,857
Accounts payable	26,370		23,102
Due to affiliated companies	9,916		5,901
Other current liabilities	151,824		144,268
Total current liabilities	199,711		195,128
Long-term debt	22,782		22,863
Other long-term liabilities	25,698		23,491
Minority interest in subsidiaries	325		239
Total shareholders’ equity	214,578		191,466
Total liabilities and shareholders’ equity	$	463,094	$	433,187

4

FOR FURTHER INFORMATION:	Michael Willett, Investor Relations Officer
	Tel: (978) 663-3660, ext. 1411
	Email: Michael.Willett@Bruker.com

5